Antimicrobial or bactericidal composition

Abstract

The object of this invention is to provide a novel antibacterial or bactericidal composition that suppresses the growth of caries bacteria and / or periodontal disease bacteria. [Solution] The active ingredient is D-aspartic acid or a salt thereof. An antibacterial or bactericidal composition that inhibits the growth of caries bacteria and / or periodontal disease bacteria.

Description

Technical Field

[0001] The present invention relates to a composition for antibacterial or bactericidal use, and a method for suppressing the growth of cariogenic bacteria and / or periodontal pathogenic bacteria.

Background Art

[0002] Tooth decay and periodontal disease are respectively caused by cariogenic bacteria and periodontal pathogenic bacteria. Substances showing antibacterial activity against cariogenic bacteria and periodontal pathogenic bacteria have been conventionally known for the prevention or treatment of oral diseases such as tooth decay and periodontal disease.

[0003] For example, Patent Document 1 discloses the antibacterial action against cariogenic bacteria, Candida bacteria, periodontal pathogenic bacteria, etc. of the cells or cell cultures or extracts thereof of Lactobacillus rhamnosus NITE P-1559 strain, and at least one or more cells or cell cultures or extracts thereof selected from the group consisting of Lactobacillus rhamnosus NITE BP-771 strain, Lactobacillus casei NITE BP-772 strain, and Lactobacillus paracasei NITE BP-775 strain.

[0004] In addition, Patent Document 2 discloses the antibacterial activity of Lactobacillus rhamnosus NITE BP-771 strain, Lactobacillus casei NITE BP-772 strain, and Lactobacillus paracasei NITE BP-775 strain against cariogenic bacteria, Candida bacteria, and periodontal pathogenic bacteria.

[0005] Furthermore, Patent Document 3 shows that bacteriocins extracted from bacterial cultures of Lactobacillus rhamnosus NITE P-1065 strain and Lactobacillus rhamnosus NITE BP-771 strain suppress the growth of caries bacteria, Candida, and periodontal disease bacteria.

[0006] Furthermore, Patent Document 4 shows the antibacterial activity of the culture supernatant of Lactobacillus rhamnosus NITE P-1558 strain and Lactobacillus rhamnosus NITE P-1559 strain against caries bacteria, Candida, and periodontal disease bacteria. [Prior art documents] [Patent Documents]

[0007] [Patent Document 1] Japanese Patent Publication No. 2018-100228 [Patent Document 2] International Publication No. 2011 / 007584 [Patent Document 3] International Publication No. 2012 / 108518 [Patent Document 4] Japanese Patent Publication No. 2014-218491 [Overview of the Initiative] [Problems that the invention aims to solve]

[0008] The object of this invention is to provide a novel antibacterial or bactericidal composition that suppresses the growth of caries bacteria and / or periodontal disease bacteria. [Means for solving the problem]

[0009] The present invention, which solves the above problems, is as follows.

[0010] [1] An antibacterial or bactericidal composition comprising D-aspartic acid or a salt thereof as an active ingredient, which inhibits the growth of caries bacteria and / or periodontal disease bacteria.

[0011] [2] The antibacterial or bactericidal composition according to [1], wherein the caries bacterium is Streptococcus mutans and the periodontal disease bacterium is Aggregatibacter actinomycetemcomitans.

[0012] [3] The antimicrobial composition according to [1] or [2], wherein the concentration of D-aspartic acid or its salt is 12.5 mM or higher.

[0013] [4] The bactericidal composition according to [1] or [2], wherein the concentration of D-aspartic acid or its salt is 250 mM or more.

[0014] [5] An antibacterial or bactericidal composition according to any one of [1] to [4], which is at least one dosage form selected from the group consisting of toothpaste, mouthwash, oral cleanser, oral spray, oral ointment, oral varnish, mouthwash, gum massage cream, oral gel, moisturizer, sublingual tablet, and food.

[0015] A method for suppressing the growth of caries bacteria and / or periodontal disease bacteria, characterized by applying an antibacterial or bactericidal composition described in any one of items [1] to [5] to the oral cavity. [Effects of the Invention]

[0016] According to the present invention, it is possible to provide an antibacterial or bactericidal composition that suppresses the growth of caries bacteria and / or periodontal disease bacteria. [Brief explanation of the drawing]

[0017] [Figure 1] This is a photograph of the plate after culture in Test Example 1, to which D-aspartic acid was added. [Figure 2] This is a photograph of the plate after culture in Test Example 1, to which D-serine was added. [Figure 3] This is a photograph of the plate after culture in Test Example 1, to which D-alanine was added. [Figure 4] It is a graph showing the growth degree (% growth) of Streptococcus mutans at each concentration of D - aspartic acid in Test Example 1. [Figure 5] It is a graph showing the growth degree (% growth) of Streptococcus mutans at each concentration of DL - aspartic acid in Test Example 2. [Figure 6] It is a graph showing the growth degree (% growth) of Streptococcus mutans at each concentration of L - aspartic acid in Test Example 2. [Figure 7] In Test Example 2, it is a photograph showing the result of spot plating of a sample to which D - aspartic acid was added to Streptococcus mutans. [Figure 8] In Test Example 2, it is a photograph showing the result of spot plating of a sample to which DL - aspartic acid was added to Streptococcus mutans. [Figure 9] It is a graph showing the growth degree (% growth) of Aggregatibacter actinomycetemcomitans at each concentration of DL - aspartic acid in Test Example 2. [Figure 10] It is a graph showing the growth degree (% growth) of Aggregatibacter actinomycetemcomitans at each concentration of L - aspartic acid in Test Example 2. [Figure 11] In Test Example 2, it is a photograph of the plate after culturing with DL - aspartic acid added. [Figure 12]This is a photograph showing the spot plating results of a sample of Aggregatibacter actinomycetemcomitans to which D-aspartic acid was added, as in Test Example 2. [Figure 13] This graph shows the inhibitory effect of various concentrations of D-aspartic acid on the formation of biofilms derived from Streptococcus mutans in Test Example 3. [Figure 14] This graph shows the inhibitory effect of various concentrations of D-aspartic acid on the formation of biofilms derived from Aggregatibacter actinomycetemcomitans in Test Example 3. [Modes for carrying out the invention]

[0018] The following describes embodiments of the present invention to facilitate understanding of the invention. Note that the following embodiments are examples of the present invention and can be modified as appropriate within the scope of the claims.

[0019] <1> Antimicrobial or bactericidal composition The present invention relates to an antibacterial or bactericidal composition containing D-aspartic acid or a salt thereof as an active ingredient, which inhibits the growth of caries bacteria and / or periodontal disease bacteria.

[0020] Examples of salts of D-aspartic acid include acid addition salts, metal salts, ammonium salts, and organic amine addition salts. Examples of metal salts include alkali metal salts such as sodium salts and potassium salts, alkaline earth metal salts such as magnesium salts and calcium salts, aluminum salts, and zinc salts.

[0021] Examples of caries-causing bacteria include Streptococcus mutans and Streptococcus sobrinus.

[0022] Examples of periodontal disease bacteria include Aggregatibacter actinomycetemcomitans, Actinobacillus actinomycetemcomitans, Porphyromonas gingivalis, Prevotella intermedia, Treponema denticola, Tannerella forsythensis, and Fusobacterium nucleatum.

[0023] When the present invention is used as an antibacterial composition, the concentration of D-aspartic acid or its salt is preferably 12.5 mM or higher, more preferably 20 mM or higher, and even more preferably 30 mM. Furthermore, the concentration of D-aspartic acid or its salt is preferably 1000 mM or less, more preferably 800 mM or less, and even more preferably 500 mM or less. When the present invention is used as an antibacterial composition, the concentration of D-aspartic acid or its salt is preferably 0.17 wt% or more, more preferably 0.27 wt% or more, and even more preferably 0.40 wt% or more. Furthermore, the concentration of D-aspartic acid or its salt is preferably 13 wt% or less, more preferably 11 wt% or less, and even more preferably 7 wt% or less.

[0024] Furthermore, when the present invention is used as a sterilizing composition, the concentration of D-aspartic acid or its salt is preferably 250 mM or higher, more preferably 300 mM or higher, and even more preferably 400 mM or higher. Furthermore, the concentration of D-aspartic acid or its salt is preferably 5M or less, more preferably 3M or less, and even more preferably 1M or less. Furthermore, when the present invention is used as a sterilizing composition, the concentration of D-aspartic acid or its salt is preferably 3.3 wt% or more, more preferably 4.0 wt% or more, and even more preferably 5.3 wt% or more. Furthermore, the concentration of D-aspartic acid or its salt is preferably 67 wt% or less, more preferably 40 wt% or less, and even more preferably 13 wt% or less.

[0025] The dosage form of the antibacterial or bactericidal composition according to the present invention is not particularly limited, but it is preferably applied to the oral cavity. Specifically, it is preferably at least one dosage form selected from the group consisting of toothpaste, mouthwash, oral cleanser, oral spray, oral ointment, oral varnish, mouthwash, gum massage cream, oral gel, moisturizer, sublingual tablet, and food. Examples of food products include orally disintegrating films, chewable tablets, granules, gum, gummies,ラムネ (ramune), and candies.

[0026] Furthermore, the longer the antibacterial or bactericidal composition is applied to the oral cavity, the higher the antibacterial or bactericidal effect it can exhibit. Therefore, it is preferable that the antibacterial or bactericidal composition according to the present invention be in a form that does not need to be rinsed off after application to the oral cavity.

[0027] Furthermore, while the antibacterial or bactericidal composition according to the present invention contains D-aspartic acid or a salt thereof as an active ingredient, this does not exclude compositions containing L-aspartic acid or a salt thereof. In other words, the antibacterial or bactericidal composition according to the present invention may contain both D-aspartic acid or a salt thereof and L-aspartic acid or a salt thereof. The proportion of D-aspartic acid or its salt contained in total aspartic acid or its salt is preferably 30% or more, more preferably 50% or more, and even more preferably 80% or more.

[0028] Furthermore, the present invention is preferably an antibacterial or bactericidal composition for the prevention or improvement of oral diseases. Oral diseases include dental caries and periodontal disease.

[0029] The antibacterial or sterilizing composition according to the present invention is preferably in a form that indicates its use, such as "antibacterial," "sterilizing," "for the prevention or improvement of oral diseases," "for the prevention or improvement of dental caries," or "for the prevention or improvement of periodontal disease."

[0030] The aforementioned "display" includes all displays that have the function of informing consumers of the aforementioned use. In other words, any display that can evoke or infer the aforementioned use falls under the category of "display," regardless of the purpose of the display, the content of the display, or the object or medium of the display. Furthermore, the phrase "labeled" means that there is a labeling act that aims to associate the label with an antibacterial or sterilizing composition, etc. (product).

[0031] The act of labeling is preferably one that allows consumers to directly recognize the intended use. Specifically, examples include the act of describing the intended use on the product or its packaging, and the act of describing the intended use on advertisements, price lists, or transaction documents (including those provided by electronic means) relating to the product.

[0032] <2> Method for inhibiting the growth of caries bacteria and / or periodontal disease bacteria This invention is also a method for suppressing the growth of caries bacteria and / or periodontal disease bacteria. Specifically, <1> This method involves applying an antibacterial or bactericidal composition, as described above, to the oral cavity to suppress the growth of caries bacteria and / or periodontal disease bacteria.

[0033] The time for applying the antibacterial or bactericidal composition to the oral cavity is preferably 30 seconds or more, more preferably 1 minute or more, and even more preferably 5 minutes or more. The time for applying the antibacterial or bactericidal composition to the oral cavity is preferably 3 hours or less, more preferably 2 hours or less, and even more preferably 1 hour or less. The longer an antibacterial or bactericidal composition is applied to the oral cavity, the higher its antibacterial or bactericidal effect can be achieved.

[0034] In the method for suppressing the growth of caries bacteria and / or periodontal disease bacteria according to the present invention, it is preferable not to rinse the oral cavity after applying the antibacterial or bactericidal composition. By not rinsing the oral cavity, the time for which the antibacterial or bactericidal composition is applied to the oral cavity can be extended, and a high antibacterial or bactericidal effect can be exerted.

[0035] The method according to the present invention can be performed by users of the antibacterial or sterilizing composition according to the present invention. Herein, the method of use according to the present invention does not involve medical procedures. Furthermore, the method of use according to the present invention is a non-therapeutic method. [Examples]

[0036] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to the following examples unless it exceeds the essence of the invention.

[0037] <Test Example 1> The following tests investigated the antibacterial effect of D-amino acids on biofilms derived from Streptococcus mutans (hereinafter also referred to as S. mutans).

[0038] The following three types of D-amino acids were used. D-Aspartic acid (TCI♯A0545 solvent; 10% HCl) D-Alanine (TCI♯A0177 solvent; DW) D-Serine (TCI#S0033 solvent; DW)

[0039] The antibacterial effect of D-amino acids on S. mutans was investigated using the following procedure. First, S. mutans was incubated from a glycerol stock. After 24 hours, S. mutans colonies were picked and cultured in liquid medium. Next, OD 600 S. mutans, adjusted to a concentration of 0.5, was dispensed in 300 μL portions into each well of a 96-well plate. This plate was incubated for 24 hours under conditions of 5% carbon dioxide concentration and 37°C. After incubation, the plate was washed three times with deionized water (DW), then allowed to stand at 37°C for 20 minutes and air-dried. In addition, a 100 mM D-amino acid solution was prepared. Furthermore, 200 μL of the 100 mM D-amino acid solution was repeatedly diluted by a 1 / 2 dilution ratio and dispensed into each well of the plate. The plate was left to stand at 37°C for 30 minutes to allow the reaction to proceed. The plate was then washed once with DW, and 200 μL of BHI medium was added to each well. This plate was incubated for 16 hours under conditions of 5% carbon dioxide concentration and 37°C. Finally, the absorbance at a wavelength of 630 nm was measured using a spectrophotometer. In addition, the absorbance at 630 nm of a non-irritating bacterial culture solution (control) was measured separately. The absorbance of each sample was divided by the absorbance of the control and multiplied by 100 to calculate the growth rate (%growth).

[0040] Table 1 shows the growth rate (%growth) of S. mutans at each concentration of D-aspartic acid, D-serine, and D-alanine.

[0041] [Table 1]

[0042] Furthermore, Figure 1 shows photographs of plates after culture with D-aspartic acid added, Figure 2 shows D-serine added, and Figure 3 shows D-alanine added. In Figures 1 to 3, the left side shows a high concentration of D-amino acids, and the right side shows a low concentration of D-amino acids. In Figure 1, the four samples from the left (D-aspartic acid concentration of 12.5 mM or higher) can be visually confirmed to be highly transparent. On the other hand, in Figures 2 (D-serine) and 3 (D-alanine), color is present at all concentrations. Figure 4 also shows the growth rate (%growth) of S. mutans at various concentrations of D-aspartic acid.

[0043] As shown in Table 1 and Figures 1-4, among the three D-amino acids, treatment with a solvent of 12.5 mM or higher showed an inhibitory effect on S. mutans growth. Furthermore, it was found that the higher the concentration of D-aspartic acid, the greater the inhibitory effect on S. mutans growth. On the other hand, D-serine and D-alanine did not show any growth-inhibiting effect on S. mutans.

[0044] <Test Example 2> The following tests investigated the antibacterial and bactericidal effects of amino acids on biofilms derived from S. mutans and Aggregatibacter actinomycetemcomitans (hereinafter also referred to as A. actinomycetemcomitans).

[0045] The following three types of amino acids were used. D-Aspartic acid (TCI♯A0545 solvent; 10% HCl) ·L-Aspartic acid(TCI#A0546 solvent;10%HCL) DL-Aspartic acid (TCI♯A0544 solvent; 10% HCl)

[0046] The antibacterial effects of amino acids against S. mutans and A. actinomycetemcomitans were investigated using the following procedure. First, S. mutans and A. actinomycetemcomitans were incubated from glycerol stocks. After 24 hours, colonies were picked and cultured in liquid medium. Next, OD 600 S. mutans and A. actinomycetemcomitans, adjusted to a ratio of 0.5, were dispensed in 300 μL portions into each well of a 96-well plate. This plate was incubated for 24 hours under conditions of 5% carbon dioxide concentration and 37°C. After incubation, the plate was washed three times with deionized water (DW), then allowed to stand at 37°C for 20 minutes and air-dried. The amino acid solution was repeatedly diluted by a 1 / 2 dilution ratio and dispensed into each well of the plate in 200 μL increments. The plate was left to stand at 37°C for 30 minutes to allow the reaction to proceed. The plates were then washed once with DW, and 200 μL of BHI medium was added to each well. The plates were incubated for 16 hours under conditions of 5% carbon dioxide concentration and 37°C. Finally, the absorbance at a wavelength of 630 nm was measured using a spectrophotometer. In addition, the absorbance at 630 nm of a non-irritating bacterial culture solution (control) was measured separately. The absorbance of each sample was divided by the absorbance of the control and multiplied by 100 to calculate the growth rate (%growth).

[0047] Furthermore, spot plating was performed on some samples to calculate the minimum bactericidal concentration (MBC) of amino acids against S. mutans and A. actinomycetemcomitans. Specifically, 5 μL of sample was taken from some wells and dropped onto BHI agar. This agar was incubated for 24 hours under conditions of 5% carbon dioxide concentration and 37°C, and the presence or absence of colony formation was checked. For concentration ranges where no colonies formed, it was determined that the substance had a bactericidal effect.

[0048] Table 2 shows the growth rate (%growth) of S. mutans at various concentrations of DL-aspartic acid and L-aspartic acid.

[0049] [Table 2]

[0050] Furthermore, Figure 5 shows the growth rate (%growth) of S. mutans at various concentrations of DL-aspartic acid, and Figure 6 shows the growth rate (%growth) of S. mutans at various concentrations of L-aspartic acid.

[0051] As shown in Table 2, Figure 5, and Figure 6, treatment with DL-aspartic acid at a solvent concentration of 31.25 mM or higher inhibited the growth of S. mutans. Furthermore, it was observed that the higher the concentration of DL-aspartic acid, the greater the inhibitory effect on S. mutans growth. On the other hand, L-aspartic acid did not show any growth-inhibiting effect on S. mutans. Furthermore, while L-aspartic acid did not show an inhibitory effect on S. mutans growth, DL-aspartic acid did. Therefore, it is considered that L-aspartic acid does not inhibit the growth-inhibiting effect of D-aspartic acid.

[0052] Figures 7 and 8 show the results of spot plating. Figure 7 is a photograph of a sample of S. mutans to which D-aspartic acid was added, and Figure 8 is a photograph of a sample of S. mutans to which DL-aspartic acid was added, after spot plating. The numbers in the figures represent the concentrations of D-aspartic acid and DL-aspartic acid, with 1 corresponding to 500 mM, 2 to 250 mM, 3 to 125 mM, and 4 to 62.5 mM. As shown in Figure 7, no colonies were formed for D-aspartic acid at concentrations above 250 mM. Furthermore, as shown in Figure 8, only a few colonies were formed for DL-aspartic acid at 250 mM, and no colonies were formed at 500 mM. Based on the above, the minimum bactericidal concentration (MBC) for D-aspartic acid against S. mutans was 250 mM, and the MBC for DL-aspartic acid was 500 mM.

[0053] Table 3 also shows the growth rate (%growth) of A. actinomycetemcomitans at various concentrations of DL-aspartic acid and L-aspartic acid.

[0054] [Table 3]

[0055] Furthermore, Figure 9 shows the growth rate (%growth) of A. actinomycetemcomitans at various concentrations of DL-aspartic acid, and Figure 10 shows the growth rate (%growth) of A. actinomycetemcomitans at various concentrations of L-aspartic acid. Figure 11 also shows a photograph of a plate after culture with DL-aspartic acid added. In Figure 11, the left side shows a high concentration of amino acids, and the right side shows a low concentration of amino acids. In Figure 11, the five samples from the left (with a DL-aspartic acid concentration of 31.3 mM or higher) can be visually confirmed to have high transparency.

[0056] As shown in Table 3 and Figures 9-11, treatment with DL-aspartic acid at a concentration of 31.3 mM or higher inhibited the growth of A. actinomycetemcomitans. Furthermore, it was observed that the higher the concentration of DL-aspartic acid, the greater the inhibitory effect on A. actinomycetemcomitans growth. On the other hand, L-aspartic acid did not show any growth-inhibiting effect on A. actinomycetemcomitans. Furthermore, while L-aspartic acid did not show any growth-inhibiting effect on A. actinomycetemcomitans, DL-aspartic acid did. Therefore, it is thought that D-aspartic acid, which is contained in DL-aspartic acid, has a growth-inhibiting effect on A. actinomycetemcomitans. In addition, it is thought that L-aspartic acid does not inhibit the growth-inhibiting effect of D-aspartic acid.

[0057] Figure 12 shows the results of spot plating. Figure 12 is a photograph of a sample of A. actinomycetemcomitans to which D-aspartic acid was added, after spot plating. The numbers in the figure represent the concentration of D-aspartic acid, with 1 corresponding to 500 mM, 2 to 250 mM, 3 to 125 mM, and 4 to 62.5 mM. As shown in Figure 12, no colonies were formed at concentrations above 250 mM for D-aspartic acid. Based on the above, the minimum bactericidal concentration (MBC) of D-aspartic acid against A. actinomycetemcomitans was 250 mM.

[0058] <Test Example 3> The following tests confirmed the effects of D-aspartic acid on biofilm formation from S. mutans and A. actinomycetemcomitans using crystal violet staining.

[0059] The following D-aspartic acid was used. D-Aspartic acid (TCI♯A0545 solvent; 10% HCl)

[0060] The following kits were used for the experiment. ·Biofilm Formation Assay Kit(DOJINDO)

[0061] The bacterial suspensions of S. mutans and A. actinomycetemcomitans were measured at optical density (OD). 600 After adjusting the concentration to 0.5, 180 μL was seeded into each well of a 96-well plate (Plate 1). Next, a 500 mM D-aspartic acid solution was prepared and dispensed into each well of Plate 1 in 180 μL in repeated 1 / 2 dilutions. Furthermore, the 96-peg lid provided in the kit was placed over Plate 1 and incubated for 24 hours under conditions of 5% carbon dioxide concentration and 37°C to allow a biofilm to form on the 96-peg lid. Next, 200 μL of a 500 mM D-aspartic acid solution, without bacterial suspension, was dispensed into another 96-well plate (Plate 2) in repeated 1 / 2 dilutions. Then, the 96-peg lid from Plate 1 was placed over Plate 2, and the plates were incubated at 37°C with a carbon dioxide concentration of 5% for 72 hours to treat with D-aspartic acid. Next, 200 μL of physiological saline was dispensed into two different plates (plate 3 and plate 4), and 200 μL of crystal violet solution was dispensed into plate 5. The 96-peg lid placed on plate 2 was gently immersed in plates 3 and 4 and washed with physiological saline. Then, it was placed on plate 5 and left to stand at room temperature for 30 minutes. The biofilm formed on the 96-peg lid was then stained with crystal violet solution. Furthermore, 200 μL of physiological saline was dispensed into separate plates (plate 6 and plate 7), and 200 μL of ethanol was dispensed into plate 8. The 96-peg lid placed over plate 5 was gently immersed in plates 6 and 7 and washed with physiological saline. After that, it was placed over plate 8 and left to stand at room temperature for 15 minutes, and the dye was extracted into plate 8 with ethanol. Finally, the 96-peg lid was removed, and the absorbance at a wavelength of 590 nm was measured using a spectrophotometer to determine the amount of crystal violet pigment remaining on plate 8 (i.e., the amount adsorbed by the biofilm).

[0062] Table 4 and Figure 13 show the inhibitory effect of D-aspartic acid on the formation of S. mutans-derived biofilms at various concentrations. Note that the upper right photograph in Figure 13 shows the plate after the reaction; the left side shows a higher concentration of D-aspartic acid, while the right side shows a lower concentration.

[0063] [Table 4]

[0064] As shown in Table 4 and Figure 13, it was observed that the inhibitory effect on the formation of S. mutans-derived biofilms increased with increasing concentration of D-aspartic acid. In particular, the formation of S. mutans-derived biofilms was inhibited under conditions of a D-aspartic acid concentration of 250 mM.

[0065] Table 5 and Figure 14 show the inhibitory effect of D-aspartic acid on the formation of biofilms derived from A. actinomycetemcomitans at various concentrations. Note that the upper right photograph in Figure 14 shows the plate after the reaction; the left side shows a low concentration of D-aspartic acid, while the right side shows a high concentration.

[0066] [Table 5]

[0067] As shown in Table 5 and Figure 14, it was observed that the inhibitory effect on biofilm formation derived from A. actinomycetemcomitans increased with increasing concentration of D-aspartic acid. In particular, the formation of biofilms derived from A. actinomycetemcomitans was inhibited under conditions of a D-aspartic acid concentration of 250 mM. [Industrial applicability]

[0068] According to the present invention, an antibacterial or sterilizing composition can be provided.

Claims

1. The active ingredient is D-aspartic acid or a salt thereof. An antibacterial or bactericidal composition that inhibits the growth of caries bacteria and / or periodontal disease bacteria.

2. The aforementioned caries bacterium is Spletococcus mutans. The aforementioned periodontal disease bacterium is Aggregatibacter actinomycetemcomitans. The antibacterial or bactericidal composition according to claim 1.

3. The concentration of the D-aspartic acid or its salt is 12.5 mM or higher. The antibacterial composition according to claim 1.

4. The concentration of the D-aspartic acid or its salt is 250 mM or higher. The bactericidal composition according to claim 1.

5. At least one dosage form selected from the group consisting of toothpaste, mouthwash, oral cleanser, oral spray, oral ointment, oral varnish, mouthwash, gum massage cream, oral gel, moisturizer, sublingual tablet, and food. The antibacterial or bactericidal composition according to claim 1.

6. The antibacterial or bactericidal composition described in any one of claims 1 to 5 is applied to the oral cavity. A method for suppressing the growth of caries bacteria and / or periodontal disease bacteria.

Images